# Comparison of 46 Cytokines in Peripheral Blood Between Patients with Papillary Thyroid Cancer and Healthy Individuals with AI-Driven Analysis to Distinguish Between the Two Groups

**Authors:** Kyung-Jin Bae, Jun-Hyung Bae, Ae-Chin Oh, Chi-Hyun Cho

PMC · DOI: 10.3390/diagnostics15060791 · Diagnostics · 2025-03-20

## TL;DR

This study compares 46 cytokines in blood samples from papillary thyroid cancer patients and healthy individuals, using AI to identify key differences and improve classification accuracy.

## Contribution

The novel use of AI algorithms, particularly XGBoost, to classify PTC patients based on 46 cytokines simultaneously, identifying EGF and IL-10 as critical biomarkers.

## Key findings

- XGBoost outperformed other AI algorithms in classifying PTC patients versus controls.
- Ten cytokines were significantly higher in PTC patients, while five were significantly lower.
- EGF and IL-10 were identified as key contributors to distinguishing PTC patients from healthy controls.

## Abstract

Background: Recent studies have analyzed some cytokines in patients with papillary thyroid carcinoma (PTC), but simultaneous analysis of multiple cytokines remains rare. Nonetheless, the simultaneous assessment of multiple cytokines is increasingly recognized as crucial for understanding the cytokine characteristics and developmental mechanisms in PTC. In addition, studies applying artificial intelligence (AI) to discriminate patients with PTC based on serum multiple cytokine data have been performed rarely. Here, we measured and compared 46 cytokines in patients with PTC and healthy individuals, applying AI algorithms to classify the two groups. Methods: Blood serum was isolated from 63 patients with PTC and 63 control individuals. Forty-six cytokines were analyzed simultaneously using Luminex assay Human XL Cytokine Panel. Several laboratory findings were identified from electronic medical records. Student’s t-test or the Mann–Whitney U test were performed to analyze the difference between the two groups. As AI classification algorithms to categorize patients with PTC, K-nearest neighbor function, Naïve Bayes classifier, logistic regression, support vector machine, and eXtreme Gradient Boosting (XGBoost) were employed. The SHAP analysis assessed how individual parameters influence the classification of patients with PTC. Results: Cytokine levels, including GM-CSF, IFN-γ, IL-1ra, IL-7, IL-10, IL-12p40, IL-15, CCL20/MIP-α, CCL5/RANTES, and TNF-α, were significantly higher in PTC than in controls. Conversely, CD40 Ligand, EGF, IL-1β, PDGF-AA, and TGF-α exhibited significantly lower concentrations in PTC compared to controls. Among the five classification algorithms evaluated, XGBoost demonstrated superior performance in terms of accuracy, precision, sensitivity (recall), specificity, F1-score, and ROC-AUC score. Notably, EGF and IL-10 were identified as critical cytokines that significantly contributed to the differentiation of patients with PTC. Conclusions: A total of 5 cytokines showed lower levels in the PTC group than in the control, while 10 cytokines showed higher levels. While XGBoost demonstrated the best performance in discriminating between the PTC group and the control group, EGF and IL-10 were considered to be closely associated with PTC.

## Linked entities

- **Proteins:** CSF2 (colony stimulating factor 2), IFNG (interferon gamma), IL1R1 (interleukin 1 receptor type 1), IL7 (interleukin 7), IL10 (interleukin 10), Il12b (interleukin 12b), IL15 (interleukin 15), TNF (tumor necrosis factor), EGF (epidermal growth factor), IL1B (interleukin 1 beta), pdgfaa (platelet-derived growth factor alpha polypeptide a), TGFA (transforming growth factor alpha)
- **Diseases:** papillary thyroid carcinoma (MONDO:0005075), papillary thyroid cancer (MONDO:0005075)

## Full-text entities

- **Genes:** IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CCL5 (C-C motif chemokine ligand 5) [NCBI Gene 6352] {aka D17S136E, RANTES, SCYA5, SIS-delta, SISd, TCP228}, IL7 (interleukin 7) [NCBI Gene 3574] {aka IL-7, IMD130}, CD40LG (CD40 ligand) [NCBI Gene 959] {aka CD154, CD40L, HIGM1, IGM, IMD3, T-BAM}, ITIH1 (inter-alpha-trypsin inhibitor heavy chain 1) [NCBI Gene 3697] {aka H1P, IATIH, ITI-HC1, ITIH, SHAP}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL1RN (interleukin 1 receptor antagonist) [NCBI Gene 3557] {aka CRMO2, DIRA, ICIL-1RA, IL-1RN, IL-1ra, IL-1ra3}, EGF (epidermal growth factor) [NCBI Gene 1950] {aka HOMG4, URG}, CCL20 (C-C motif chemokine ligand 20) [NCBI Gene 6364] {aka CKb4, Exodus, LARC, MIP-3-alpha, MIP-3a, MIP3A}, IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, TGFA (transforming growth factor alpha) [NCBI Gene 7039] {aka TFGA}
- **Diseases:** PTC (MESH:D000077273)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11940922/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11940922/full.md

## References

56 references — full list in the complete paper: https://tomesphere.com/paper/PMC11940922/full.md

---
Source: https://tomesphere.com/paper/PMC11940922